A Randomized, Open-label, Single Dose, 3-way Crossover Clinical Trial to Investigate the Effect of Food on the Pharmacokinetics of HSG4112 in Healthy Male Volunteers
Latest Information Update: 22 May 2024
At a glance
- Drugs Vutiglabridin (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity
- Focus Pharmacokinetics
- Sponsors Glaceum
- 29 Mar 2024 Results evaluating the effect of food in the single-dose study, presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 23 Sep 2021 Status changed from active, no longer recruiting to completed.